Rathbones Group’s AbbVie ABBV Stock Holding History

Rathbones Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.5M	Sell	66,480 -364	-0.5%	-$80.7K	0.06%	145
2025 Q4	$15.3M	Sell	66,844 -4,791	-7%	-$1.09M	0.06%	145
2025 Q3	$16.6M	Sell	71,635 -78	-0.1%	-$15.9K	0.07%	135
2025 Q2	$13.3M	Sell	71,713 -2,143	-3%	-$398K	0.06%	147
2025 Q1	$15.5M	Sell	73,856 -5,572	-7%	-$1.08M	0.07%	141
2024 Q4	$14.1M	Sell	79,428 -10,327	-12%	-$1.9M	0.07%	144
2024 Q3	$17.7M	Sell	89,755 -4,529	-5%	-$845K	0.09%	128
2024 Q2	$16.2M	Sell	94,284 -4,039	-4%	-$669K	0.09%	126
2024 Q1	$17.9M	Sell	98,323 -7,961	-7%	-$1.37M	0.1%	120
2023 Q4	$16.5M	Sell	106,284 -2,922	-3%	-$426K	0.11%	124
2023 Q3	$16.3M	Buy	109,206 +16,280	+18%	+$2.39M	0.12%	122
2023 Q2	$12.5M	Sell	92,926 -1,720	-2%	-$252K	0.12%	119
2023 Q1	$15.1M	Sell	94,646 -4,154	-4%	-$635K	0.15%	112
2022 Q4	$16M	Sell	98,800 -1,834	-2%	-$281K	0.18%	109
2022 Q3	$13.5M	Buy	100,634 +17	+0%	+$2.44K	0.17%	111
2022 Q2	$15.4M	Sell	100,617 -557	-0.6%	-$85.1K	0.18%	109
2022 Q1	$16.4M	Sell	101,174 -535	-0.5%	-$77.7K	0.17%	109
2021 Q4	$13.8M	Buy	101,709 +594	+0.6%	+$70.2K	0.13%	113
2021 Q3	$10.9M	Sell	101,115 -4,898	-5%	-$560K	0.12%	119
2021 Q2	$11.9M	Buy	106,013 +1,209	+1%	+$136K	0.13%	112
2021 Q1	$11.3M	Buy	104,804 +1,146	+1%	+$123K	0.15%	109
2020 Q4	$11.1M	Sell	103,658 -4,684	-4%	-$450K	0.16%	102
2020 Q3	$9.49M	Sell	108,342 -1,014	-0.9%	-$95.5K	0.16%	92
2020 Q2	$10.7M	Sell	109,356 -2,293	-2%	-$202K	0.22%	85
2020 Q1	$8.51M	Sell	111,649 -371	-0.3%	-$31.6K	0.25%	81
2019 Q4	$9.92M	Buy	112,020 +1,571	+1%	+$130K	0.26%	80
2019 Q3	$8.36M	Buy	110,449 +37,314	+51%	+$2.56M	0.24%	82
2019 Q2	$5.32M	Sell	73,135 -5,720	-7%	-$450K	0.17%	95
2019 Q1	$6.36M	Sell	78,855 -4,545	-5%	-$372K	0.21%	89
2018 Q4	$7.69M	Sell	83,400 -4,175	-5%	-$367K	0.29%	73
2018 Q3	$8.28M	Sell	87,575 -300	-0.3%	-$28.4K	0.28%	69
2018 Q2	$8.14M	Sell	87,875 -7,550	-8%	-$737K	0.31%	70
2018 Q1	$9.03M	Sell	95,425 -8,840	-8%	-$971K	0.37%	68
2017 Q4	$10.1M	Sell	104,265 -770	-0.7%	-$72.6K	0.41%	65
2017 Q3	$9.33M	Sell	105,035 -1,532	-1%	-$117K	0.41%	65
2017 Q2	$7.73M	Sell	106,567 -2,370	-2%	-$159K	0.34%	73
2017 Q1	$7.1M	Sell	108,937 -237	-0.2%	-$14.9K	0.32%	75
2016 Q4	$6.84M	Sell	109,174 -26,820	-20%	-$1.64M	0.34%	73
2016 Q3	$8.58M	Sell	135,994 -1,096	-0.8%	-$71K	0.44%	65
2016 Q2	$8.49M	Sell	137,090 -7,628	-5%	-$465K	0.47%	60
2016 Q1	$8.27M	Sell	144,718 -19,320	-12%	-$1.08M	0.5%	53
2015 Q4	$8.95M	Buy	164,038 +1,450	+0.9%	+$83.5K	0.57%	54
2015 Q3	$8.85M	Buy	162,588 +5,470	+3%	+$356K	0.59%	56
2015 Q2	$10.6M	Buy	157,118 +4,480	+3%	+$292K	0.69%	55
2015 Q1	$8.94M	Sell	152,638 -2,361	-2%	-$143K	0.59%	56
2014 Q4	$10.1M	Buy	154,999 +13,435	+9%	+$847K	0.67%	57
2014 Q3	$8.18M	Buy	141,564 +2,050	+1%	+$114K	0.57%	64
2014 Q2	$7.87M	Sell	139,514 -4,990	-3%	-$262K	0.56%	63
2014 Q1	$7.43M	Sell	144,504 -8,773	-6%	-$443K	0.6%	65
2013 Q4	$8.1M	Sell	153,277 -28,340	-16%	-$1.39M	0.81%	55
2013 Q3	$8.12M	Sell	181,617 -4,372	-2%	-$194K	0.95%	41
2013 Q2	$7.69M	Buy	+185,989	New	+$8.13M	1.04%	38

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rathbones Group's ABBV Position: Q1 2026 in Review

Rathbones Group reduced its AbbVie (ABBV) stake by 0.54% in Q1 2026, selling an estimated $80.7K and leaving 66,480 shares worth $14.5M. The position accounts for 0.06% of the portfolio, ranked #145.

Rathbones Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.9M in Q1 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Rathbones Group held 66,480 shares of AbbVie worth $14.5M as of Q1 2026.
Rathbones Group sold 364 AbbVie shares in Q1 2026, an estimated $80.7K.
AbbVie made up 0.06% of Rathbones Group's portfolio in Q1 2026, its #145 holding.
Rathbones Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Rathbones Group's AbbVie position peaked at $17.9M in Q1 2024.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.